Bruker Corporation BRKR
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- +30.14%
- 1 year
- +55.97%
- Market cap
- 9.34B
- Revenue (ttm)
- 3.51B
- Profit margin
- -3.51%
- EPS (ttm)
- -1.10
- Shares out
- 152.36M
- Forward P/E
- 25.51
- Dividend
- 0.20 (0.34%)
- Ex-dividend date
- Sep 20, 2026
- YTD return
- +30.14%
- 1-year return
- +55.97%
- Volume
- 2.01M
- Avg volume
- 2.28M
- Open
- 59.00
- Previous close
- 58.06
- Day's range
- 58.46 – 61.66
- 52-week range
- 32.76 – 64.75
- Beta
- 1.27
- Analysts
- Buy
- Price target
- 63.83 (+4.1%)
- Earnings date
- Feb 11, 2027
5D +5.64 (+10.13%)
Key statistics
- Enterprise value
- 10.48B
- PEG ratio
- 1.52
- Price / sales
- 2.66
- Price / book
- 4.05
- Dividend yield
- 0.34%
- Payout ratio
- 38.46%
- Revenue growth
- 1.60%
- Free cash flow
- 236.74M
- Total cash
- 119.70M
- Total debt
- 1.71B
- Return on equity
- -4.79%
- Short % of float
- 16.03%
- 50-day average
- 58.97
- 200-day average
- 50.39
Analyst view
Consensus: buy
- Target (low)
- 50.00
- Target (mean)
- 63.83
- Target (high)
- 80.00
- Strong buy1
- Buy5
- Hold6
- Sell1
- Strong sell0
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate 0.83272.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | 0.90 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 0.419 | 0.56 | +0.14 | +33.65% |
| Aug 4, 2026 | Jun 30, 2026 | 0.3849 | 0.49 | +0.11 | +27.31% |
| May 6, 2026 | Mar 31, 2026 | 0.23 | 0.31 | +0.08 | +34.78% |
| Feb 12, 2026 | Dec 31, 2025 | 0.65 | 0.59 | -0.06 | -9.23% |
| Nov 3, 2025 | Sep 30, 2025 | 0.33 | 0.60 | +0.27 | +81.82% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | Citigroup | main | Neutral | Neutral |
| Nov 5, 2026 | Leerink Partners | main | Outperform | Outperform |
| Oct 14, 2026 | JP Morgan | down | Overweight | Neutral |
| Oct 13, 2026 | TD Cowen | main | Hold | Hold |
| Oct 7, 2026 | Barclays | main | Overweight | Overweight |
| Oct 1, 2026 | Guggenheim | main | Buy | Buy |
About Bruker Corporation
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bruker.com
News
Citigroup Maintains Neutral on Bruker, Raises Price Target to $64 
Leerink Partners Maintains Outperform on Bruker, Raises Price Target to $85 
Bruker Corporation (BRKR) Q3 2026 Earnings Call Transcript 
Bruker Q3 Earnings Call Highlights 
Here's What Key Metrics Tell Us About Bruker (BRKR) Q3 Earnings 
Wayfair, Lendingtree, Bruker, Zimmer Biomet And Other Big Stocks Moving Higher On Wednesday 
Bruker (BRKR) Q3 Earnings and Revenues Surpass Estimates 
Bruker Q3 2026 Earnings Call Transcript 
Bruker Q3 Adj. EPS $0.56 Beats $0.42 Estimate, Sales $874.000M Beat $868.827M Estimate - Bruker Affirms FY2026 Adj EPS Guidance of $2.10-$2.15 vs $2.12 Est; Lowers FY2026 Sales Guidance from $3.540B-$3.570B to $3.520B-$3.560B vs $3.556B Est
Your note
Sign in to keep a note on BRKR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BUSSE FALKO | Officer | Stock Award(Grant) | Aug 14, 2025 | 48,171 |
| HERMAN GERALD N | Chief Financial Officer | Stock Award(Grant) | Aug 13, 2026 | 111,354 |
| LAUKIEN FRANK H | Chief Executive Officer | Stock Award(Grant) | Aug 13, 2026 | 40,511,100 |
| LINTON WILLIAM A. | Director | Stock Award(Grant) | Feb 12, 2026 | 63,243 |
| MUNCH MARK ROBERT | Officer | Sale | Sep 14, 2026 | 134,806 |
| ORNELL JOHN A | Director | Stock Award(Grant) | Feb 12, 2026 | 39,732 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 13.28% | 20,237,425 | 1.24B | Jun 29, 2026 |
| Orbis Allan Gray Ltd | 11.77% | 17,940,076 | 1.10B | Jun 29, 2026 |
| Blackrock Inc. | 7.49% | 11,407,332 | 699.38M | Jun 29, 2026 |
| Pallas Capital Advisors Llc | 6.22% | 9,483,978 | 581.46M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.21% | 4,888,290 | 299.70M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.19% | 4,859,252 | 297.92M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 2.60% | 3,961,759 | 242.90M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.22% | 3,380,103 | 207.23M | Jun 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1.88% | 2,863,240 | 175.55M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.60% | 2,444,714 | 149.89M | Jun 29, 2026 |
| Fidelity Hastings Street Trust-Fidelity Series Large Cap Stock Fund | 1.55% | 2,358,800 | 144.62M | Sep 29, 2026 |
| Touchstone Fd.s Group TRT-Touchstone Fd.s Group TRT-Touchstone Mid Cap | 1.26% | 1,919,283 | 117.67M | Jun 29, 2026 |